NCT06508320 - A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | Biotech Hunter

Enrollment

932

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

September 25, 2025

Study Completion Date

September 25, 2025

Conditions

InfluenzaSARS-CoV-2

Interventions

BIOLOGICAL

mRNA-1083

IM injection in a deltoid muscle.

Trial Locations (17)

19107

DM Clinical Research - Philadelphia, Philadelphia

30030

Cenexel IRA, Decatur

33012

Indago Research & Health Center, Inc., Hialeah

33024

Cenexel RCA, Hollywood

33135

Suncoast Research Group, LLC DBA Flourish Research, Miami

60305

DM Clinical Research - River Forest, River Forest

66219

JCCT, Lenexa

77375

DM Clinical Research - Tomball MDC, Tomball

77478

DM Clinical Research - Sugarland, Sugar Land

78229

Clinical Trials of Texas, LLC DBA Flourish Research, San Antonio

80530

Hassman Research Institute - Berlin - CenExel - PPDS, Marlton

77065-5685

DM Clinical Research - Cyfair Clinical Research Center - PPDS, Houston

M4G 3E8

Centricity Research, Toronto

M9W 4L6

Centricity Research, Toronto

H9R4S3

Centricity Research, Pointe-Claire

J1L 0H8

Diex Recherche Sherbrooke Inc., Sherbrooke

G1V 4T3

Diex Recherche Québec Inc., Québec

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY